Ranked No. 1 in the medical devices category and No. 46 on Fast Company’s World’s 50 Most Innovative Companies list NEW YORK (March 25, 2026)—Cresilon has been named to Fast Company’s World’s 50 Most Innovative Companies of 2026. The company ranked No. 1 in the medical devices category and No. 46 overall. This marks the […]
Cresilon Named One of the World’s 50 Most Innovative Companies by Fast Company Read More »
NEW YORK—Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced that a retrospective clinical case series demonstrating the use of TRAUMAGEL®, in an emergency hemorrhagic trauma setting has been selected for a poster presentation at the 2026 Advanced Trauma Life Support® (ATLS®) Global Symposium taking place March 13-15 in
Contract awarded for products that bring improvement to healthcare industry New York (March 2, 2026)– Cresilon announced its revolutionary hemostatic gel TRAUMAGEL® has received an Innovative Technology contract from Vizient® the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded based on review of TRAUMAGEL from hospital experts who serve on one of
Cresilon Receives Innovative Technology Contract from Vizient for TRAUMAGEL Read More »
NEW YORK (August 4, 2025) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced that a case study demonstrating the clinical use of its FDA-cleared hemostatic medical device, TRAUMAGEL®, in an emergency hemorrhagic trauma setting has been selected for a poster presentation at the 2025 Military Health System
Revolutionary hemostatic gel for veterinary surgeons available in Canada through leading veterinary supply company NEW YORK (June 16, 2025) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for VETIGEL® to be sold directly to veterinary surgeons in Canada through McCarthy
Cresilon Announces International Distribution Agreement for VETIGEL with McCarthy Vet Read More »
Innovative hemostatic gel now available to EMS agencies, first responders, emergency departments, and trauma centers across the U.S. NEW YORK (January 13, 2025) – Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced the U.S. commercial launch of TRAUMAGEL®, a revolutionary plant-based hemostatic gel that controls bleeding in seconds when applied
Cresilon Announces U.S. Nationwide Launch of TRAUMAGEL Read More »
License Agreement Expands Zomedica’s Portfolio with Revolutionary Hemostatic Technology ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it had entered into a license and supply agreement with
NEW YORK, Sept. 16, 2024 — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, has been selected to exhibit TRAUMAGEL®, a first-of-its-kind hemostatic medical device with FDA 510(k) clearance for temporary external use for controlling moderate to severe bleeding, at the Vizient Innovative Technology Exchange. Vizient, Inc., the nation’s largest
Cresilon Selected to Exhibit TRAUMAGEL at Vizient Innovative Technology Exchange Read More »
Hemostatic gel designed to control moderate to severe bleeding in seconds and save lives NEW YORK August 15, 2024 – Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for TRAUMAGEL® (“TRAUMAGEL”) for temporary external use for controlling
Cresilon Receives FDA Clearance for TRAUMAGEL Read More »
